Development of chimeric peptides to facilitate the neutralisation of lipopolysaccharides during bactericidal targeting of multidrug-resistant Escherichia coli

• DOI: 10.1038/s42003-020-0761-3
• Publication Date: 2020-01-23T11:02:58Z
• Authors: Zhenlong Wang; Xuehui Liu; Da Teng; Ruoyu Mao; Ya Hao; Na Yang; Xiao Wang; Zhanzhan Li; Xiumin Wang; Jianhua Wang
• Keywords: Polymyxin; Polymyxin B

Abstract Pathogenic Escherichia coli can cause fatal diarrheal diseases in both animals and humans. However, no antibiotics or antimicrobial peptides (AMPs) adequately kill resistant bacteria clear bacterial endotoxin, lipopolysaccharide (LPS) which leads to inflammation sepsis. Here, the LPS-targeted smart chimeric (SCPs)-A6 G6 are generated by connecting LPS-targeting peptide-LBP14 killing domain-N6 via different linkers. Rigid flexible linkers retain independent biological activities from each component. SCPs-A6 exert low toxicity resistance, they more rapidly multiple-drug-resistant E. effectively neutralize LPS than N6 alone. The SCPs enhance mouse survival polymyxin B alleviate lung injuries blocking mitogen-activated protein kinase nuclear factor kappa-B p65 activation. These findings uniquely show that may be promising dual-function candidates as improved antibacterial anti-endotoxin agents treat infection